Lerdelimumab Antibody is a research-grade biosimilar monoclonal antibody targeting Glioblastoma-derived T-cell suppressor factor. It is a human IgG4-lambda antibody. Reactivity: Human. Supplied as a liquid in 0.01M PBS pH 7.4. Applications: ELISA, flow cytometry, functional assays and in vivo research. Endotoxin: < 10 EU/mg. Purity: >95% as determined by SDS-PAGE. For research use only.
Transforming growth factor beta-2 proprotein (Glioblastoma-derived T-cell suppressor factor,TGF-beta-2,LAP,G-TSF,TGFB2,Cetermin,Transforming growth factor beta-2 proprotein) is a ~47 kDa protein. Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-2 (TGF-beta-2) chains, which constitute the regulatory and active subunit of TGF-beta-2, respectively.
Product Name:
Lerdelimumab Antibody
SKU:
GXBS00043
Size:
100 µg, 1 mg
Antibody Type:
Monoclonal Antibody
Target:
Glioblastoma-derived T-cell suppressor factor
Isotype:
IgG4-lambda
Host Species:
Human
Reactivity:
Human
Applications:
ELISA, FCM, Functional assay, Research in vivo
Expression Host:
Mammalian cells
Synonyms:
CAT-152, Trabio, 285985-06-0
Purity:
>95% as determined by SDS-PAGE.
Endotoxin Level:
< 10 EU/mg
Formulation:
0.01M PBS pH 7.4.
State of Matter:
Liquid
Regulatory Status:
For research use only. Not suitable for clinical or therapeutic use.
Product Preparation:
Protein A/G purified from cell culture supernatant.
Storage and Handling:
Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
